Turkey plans to launch production of Russia’s Sputnik V vaccine against coronavirus at the facilities of its own pharmaceutical manufacturers. This was reported by Interfax with reference to the press service of the Russian Ministry of Health.
"Turkish Health Minister expressed interest in launching Sputnik V vaccine’s production at the facilities of Turkish pharmaceutical manufacturers after carrying out toxicological studies envisaged by local legislation," Russian Ministry reported.
At the meeting, Russian Health Minister Mikhail Murashko also assured his Turkish counterpart Fahrettin Koca that Russia was ready to launch toxicological studies at a certified laboratory. "The sides agreed to start implementing the agreements in the coming days," the Ministry noted.
On August 11, Russia registered the world’s first vaccine against the novel coronavirus. The vaccine, dubbed Sputnik V, was developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Health Ministry, and its clinical trials were successfully completed in June-July. The vaccine was developed on a platform that had been used for a number of other vaccines. Head of the Russian Direct Investment Fund Kirill Dmitriev stated earlier that Russia had already received requests from 20 countries to supply 1 bln doses of the vaccine.
As we reported earlier, the effectiveness of the Russian Sputnik V vaccine against coronavirus made 92% on the results of the interim analysis of the data of the third phase of the clinical trials.
“The first interim data analysis of the Sputnik V vaccine against Covid-19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy,” Russian Direct Investment Fund reported.
The fund noted that during the third phase of the trials the efficiency estimation was held among over 16,000 volunteers in 21 days after vaccination of placebo.